{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:48:46Z","timestamp":1791600526892,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite the high success rate of direct-acting antivirals (DAAs) in achieving sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma (HCC) persists in some patients. Cardiometabolic factors, including type 2 diabetes mellitus (T2DM), have been reported as risk factors for de novo HCC after SVR. However, the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on HCC development after SVR, particularly in Japanese patients, remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 512 HCV-infected patients who achieved SVR following DAA therapy were enrolled in this study. Clinical and laboratory data at 24\u00a0weeks after the end of therapy (SVR24) were assessed to determine the impact of MASLD on the development of HCC. Risk factors for HCC occurrence were analyzed using the Fine and Gray subdistribution hazard model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>During a median follow-up of 56\u00a0months, HCC developed in 33 patients (6.4%). Patients with MASLD at SVR24 had a significantly higher cumulative incidence of HCC than those without MASLD (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariable analysis identified MASLD, age, male, albumin-bilirubin-platelets (aMAP) score, and FibroScan-AST (FAST) score at SVR24 as independent risk factors for HCC development. Both aMAP and FAST scores were positively correlated with the number of cardiometabolic risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>MASLD is a significant determinant of post-SVR HCC risk among Japanese patients. Risk stratification incorporating MASLD, aMAP, and FAST scores may contribute to the development of optimized, patient-tailored HCC surveillance strategies and improve long-term outcomes in the Japanese clinical setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-025-02270-8","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T14:55:00Z","timestamp":1751900100000},"page":"1014-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients"],"prefix":"10.1007","volume":"60","author":[{"given":"Shintaro","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8287","authenticated-orcid":false,"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2270_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz185","author":"H Toyoda","year":"2019","unstructured":"Toyoda H, Atsukawa M, Uojima H, et al. Trends and efficacy of interferon-free anti\u2013hepatitis C virus therapy in the region of high prevalence of elderly patients, cirrhosis, and hepatocellular carcinoma: a real-world, nationwide, multicenter study of 10,688 patients in Japan. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz185.","journal-title":"Open Forum Infect Dis"},{"key":"2270_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","volume":"13","author":"T Ide","year":"2019","unstructured":"Ide T, Koga H, Nakano M, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int. 2019;13:293\u2013301.","journal-title":"Hepatol Int"},{"key":"2270_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25\u201332.","journal-title":"J Hepatol"},{"key":"2270_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100090","volume":"10","author":"D Ji","year":"2021","unstructured":"Ji D, Chen GF, Niu XX, et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: a prospective four-years follow-up study. Metabolism Open. 2021;10: 100090.","journal-title":"Metabolism Open"},{"key":"2270_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264\u201378.","journal-title":"Gastroenterology"},{"key":"2270_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","volume":"14","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Ogawa E, Huang CF, et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatol Int. 2020;14:1023\u201333.","journal-title":"Hepatol Int"},{"key":"2270_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/jgh.16494","volume":"39","author":"H Toyoda","year":"2024","unstructured":"Toyoda H, Tada T, Uojima H, et al. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma. J Gastroenterol Hepatol. 2024;39:949\u201354.","journal-title":"J Gastroenterol Hepatol"},{"key":"2270_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","volume":"17","author":"E Degasperi","year":"2019","unstructured":"Degasperi E, D\u2019Ambrosio R, Iavarone M, et al. Factors associated with increased risk of De Novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17:1183-91.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"24","key":"2270_CR9","first-page":"02578","volume":"S0168\u20138278","author":"CH Liu","year":"2024","unstructured":"Liu CH, Cheng PN, Fang YJ, et al. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. J Hepatol. 2024;S0168\u20138278(24):02578\u20139.","journal-title":"J Hepatol"},{"key":"2270_CR10","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2270_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hepr.13689","volume":"51","author":"Y Yamashita","year":"2021","unstructured":"Yamashita Y, Joshita S, Sugiura A, et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res. 2021;51:933\u201342.","journal-title":"Hepatol Res"},{"key":"2270_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/apt.15976","volume":"52","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, Takayama K, Hiramine S, et al. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther. 2020;52:866\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"2270_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/apt.16012","volume":"52","author":"S Joshita","year":"2020","unstructured":"Joshita S, Umemura T. Editorial: FAST score - a new predictive marker for HCC after SVR. Aliment Pharmacol Ther. 2020;52:1222\u20133.","journal-title":"Aliment Pharmacol Ther"},{"key":"2270_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","volume":"73","author":"R Fan","year":"2020","unstructured":"Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368\u201378.","journal-title":"J Hepatol"},{"key":"2270_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362\u201373.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2270_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2270_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jhep.2015.08.028","volume":"64","author":"U Saran","year":"2016","unstructured":"Saran U, Humar B, Kolly P, et al. Hepatocellular carcinoma and lifestyles. J Hepatol. 2016;64:203\u201314.","journal-title":"J Hepatol"},{"key":"2270_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ijc.26338","volume":"131","author":"W Borena","year":"2012","unstructured":"Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131:193\u2013200.","journal-title":"Int J Cancer"},{"issue":"Suppl 3","key":"2270_CR19","doi-asserted-by":"publisher","first-page":"S1041","DOI":"10.1245\/s10434-015-4796-5","volume":"22","author":"T Higashi","year":"2015","unstructured":"Higashi T, Hayashi H, Kaida T, et al. Prognostic impact of visceral fat amount and branched-chain amino acids (BCAA) in hepatocellular carcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S1041\u20137.","journal-title":"Ann Surg Oncol"},{"key":"2270_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00535-014-0973-8","volume":"50","author":"R Tateishi","year":"2015","unstructured":"Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350\u201360.","journal-title":"J Gastroenterol"},{"key":"2270_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3892\/etm.2010.167","volume":"2","author":"N Taura","year":"2011","unstructured":"Taura N, Ichikawa T, Miyake H, et al. Prevalence of type 2 diabetes mellitus in Japanese patients with hepatocellular carcinoma. Exp Ther Med. 2011;2:81\u20134.","journal-title":"Exp Ther Med"},{"key":"2270_CR22","first-page":"1415","volume":"22","author":"S Miura","year":"2009","unstructured":"Miura S, Ichikawa T, Taura N, et al. The level of fasting serum insulin, but not adiponectin, is associated with the prognosis of early stage hepatocellular carcinoma. Oncol Rep. 2009;22:1415\u201324.","journal-title":"Oncol Rep"},{"key":"2270_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.21037\/atm.2020.04.40","volume":"8","author":"V Lopez-Lopez","year":"2020","unstructured":"Lopez-Lopez V, Gomez Ruiz A, Lopez-Conesa A, et al. Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma. Ann Transl Med. 2020;8:844.","journal-title":"Ann Transl Med"},{"key":"2270_CR24","first-page":"1073","volume":"7","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001;7:1073\u20138.","journal-title":"Clin Cancer Res"},{"key":"2270_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/JHC.S454037","volume":"11","author":"SH Yang","year":"2024","unstructured":"Yang SH, He YS, Zheng SQ, et al. Triglyceride-glucose index is an independent risk factor for hepatocellular carcinoma development in patients with HBV-related liver cirrhosis. J Hepatocell Carcinoma. 2024;11:737\u201346.","journal-title":"J Hepatocell Carcinoma"},{"key":"2270_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyae053","author":"SY Nam","year":"2024","unstructured":"Nam SY, Jo J, Lee WK, et al. Factor modification in the association between high-density lipoprotein cholesterol and liver cancer risk in a nationwide cohort. Int J Epidemiol. 2024. https:\/\/doi.org\/10.1093\/ije\/dyae053.","journal-title":"Int J Epidemiol"},{"key":"2270_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/jnci\/djs372","volume":"104","author":"CP Wen","year":"2012","unstructured":"Wen CP, Lin J, Yang YC, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012;104:1599\u2013611.","journal-title":"J Natl Cancer Inst"},{"key":"2270_CR28","first-page":"533","volume":"73","author":"H-H Lee","year":"2024","unstructured":"Lee H-H, Lee HA, Kim E-J, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533\u201340.","journal-title":"Gut"},{"key":"2270_CR29","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702.","journal-title":"Gut"},{"key":"2270_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156004","volume":"160","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism. 2024;160: 156004.","journal-title":"Metabolism"},{"key":"2270_CR31","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"A De","year":"2024","unstructured":"De A, Bhagat N, Mehta M, Taneja S, et al. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J Hepatol. 2024;80:e51\u201391.","journal-title":"J Hepatol"},{"key":"2270_CR32","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO).\u3000PMID: 38851997. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","DOI":"10.1016\/j.jhep.2024.04.031"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02270-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:21:18Z","timestamp":1757208078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02270-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2270"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02270-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}